These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18334836)

  • 1. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight.
    Danese S
    Pathobiology; 2008; 75(1):22-4. PubMed ID: 18334836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
    Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
    Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis.
    Scaldaferri F; Vetrano S; Sans M; Arena V; Straface G; Stigliano E; Repici A; Sturm A; Malesci A; Panes J; Yla-Herttuala S; Fiocchi C; Danese S
    Gastroenterology; 2009 Feb; 136(2):585-95.e5. PubMed ID: 19013462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues.
    Chidlow JH; Shukla D; Grisham MB; Kevil CG
    Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G5-G18. PubMed ID: 17463183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease.
    Danese S; Scaldaferri F; Vetrano S; Stefanelli T; Graziani C; Repici A; Ricci R; Straface G; Sgambato A; Malesci A; Fiocchi C; Rutella S
    Gut; 2007 Sep; 56(9):1248-56. PubMed ID: 17317789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease.
    Hatoum OA; Heidemann J; Binion DG
    Ann N Y Acad Sci; 2006 Aug; 1072():78-97. PubMed ID: 17057192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors.
    Crawford Y; Ferrara N
    Methods Enzymol; 2008; 445():125-39. PubMed ID: 19022058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow.
    Danese S
    Curr Opin Gastroenterol; 2007 Jul; 23(4):384-9. PubMed ID: 17545773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease.
    Binion DG; Rafiee P
    Gastroenterology; 2009 Feb; 136(2):400-3. PubMed ID: 19111728
    [No Abstract]   [Full Text] [Related]  

  • 10. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
    Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
    Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of lymphatics in inflammatory bowel disease.
    Alexander JS; Chaitanya GV; Grisham MB; Boktor M
    Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1():E75-85. PubMed ID: 20961310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis in inflammatory bowel disease.
    Pousa ID; Maté J; Gisbert JP
    Eur J Clin Invest; 2008 Feb; 38(2):73-81. PubMed ID: 18226040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth factor manipulation of intestinal angiogenesis: a possible new paradigm in the management of inflammatory bowel disease.
    Thatch KA; Mendelson KG; Haber MM; Schwartz MZ
    J Surg Res; 2009 Oct; 156(2):245-9. PubMed ID: 19524260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
    Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
    Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein C pathway in inflammatory bowel disease: the missing link between inflammation and coagulation.
    Lust M; Vulcano M; Danese S
    Trends Mol Med; 2008 Jun; 14(6):237-44. PubMed ID: 18457995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 1. Inflammation, angiogenesis, and lymphangiogenesis.
    Halin C; Detmar M
    Methods Enzymol; 2008; 445():1-25. PubMed ID: 19022053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking adult neovascularization during ischemia and inflammation using Vegfr2-LacZ reporter mice.
    Heidenreich R; Murayama T; Silver M; Essl C; Asahara T; Rocken M; Breier G
    J Vasc Res; 2008; 45(5):437-44. PubMed ID: 18418002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models of inflammatory bowel disease.
    Byrne FR; Viney JL
    Curr Opin Drug Discov Devel; 2006 Mar; 9(2):207-17. PubMed ID: 16566291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.